ATCO.A

145.6

+0.17%↑

SWED.A

261.7

-0.27%↓

SHB.B

189.7

-1.4%↓

SCA.A

120.6

+0.04%↑

EVO

866.8

+0.72%↑

ATCO.A

145.6

+0.17%↑

SWED.A

261.7

-0.27%↓

SHB.B

189.7

-1.4%↓

SCA.A

120.6

+0.04%↑

EVO

866.8

+0.72%↑

ATCO.A

145.6

+0.17%↑

SWED.A

261.7

-0.27%↓

SHB.B

189.7

-1.4%↓

SCA.A

120.6

+0.04%↑

EVO

866.8

+0.72%↑

ATCO.A

145.6

+0.17%↑

SWED.A

261.7

-0.27%↓

SHB.B

189.7

-1.4%↓

SCA.A

120.6

+0.04%↑

EVO

866.8

+0.72%↑

ATCO.A

145.6

+0.17%↑

SWED.A

261.7

-0.27%↓

SHB.B

189.7

-1.4%↓

SCA.A

120.6

+0.04%↑

EVO

866.8

+0.72%↑

Search

Ratos AB (Class B)

Uždarymo kaina

35 -0.28

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

34.8

Max

35.5

Pagrindiniai rodikliai

By Trading Economics

Pajamos

706M

1.3B

Pardavimai

-1.9B

5.6B

P/E

Sektoriaus vid.

23.839

25.916

Pelnas, tenkantis vienai akcijai

1.64

Dividendų pajamingumas

3.85

Pelno marža

22.685

Darbuotojai

10,900

EBITDA

343M

878M

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

3.85%

3.70%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

162M

13B

Ankstesnė atidarymo kaina

35.28

Ankstesnė uždarymo kaina

35

Ratos AB (Class B) Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-08-04 21:42; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

2025-08-04 21:21; UTC

Uždarbis
Pagrindinės rinkos jėgos

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

2025-08-04 20:45; UTC

Uždarbis

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

2025-08-04 19:15; UTC

Pagrindinės rinkos jėgos

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

2025-08-04 23:41; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-08-04 23:41; UTC

Rinkos pokalbiai

Nikkei May Rise on Fed Stimulus Hopes

2025-08-04 23:28; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-08-04 23:28; UTC

Rinkos pokalbiai

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

2025-08-04 21:30; UTC

Uždarbis

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

2025-08-04 21:21; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

2025-08-04 21:18; UTC

Uždarbis

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

2025-08-04 20:25; UTC

Rinkos pokalbiai

India Hits Back Over Russian Oil Purchases -- Market Talk

2025-08-04 20:25; UTC

Uždarbis

Transocean 2Q Loss $938M >RIG

2025-08-04 20:25; UTC

Uždarbis

Transocean 2Q Loss/Shr $1.06 >RIG

2025-08-04 20:18; UTC

Uždarbis

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

2025-08-04 20:15; UTC

Uždarbis

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

2025-08-04 20:14; UTC

Uždarbis

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

2025-08-04 20:14; UTC

Uždarbis

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

2025-08-04 20:14; UTC

Uždarbis

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

2025-08-04 20:13; UTC

Uždarbis

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

2025-08-04 20:09; UTC

Uždarbis

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

2025-08-04 20:06; UTC

Uždarbis

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

2025-08-04 20:01; UTC

Uždarbis

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

2025-08-04 20:01; UTC

Uždarbis

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

2025-08-04 20:01; UTC

Uždarbis

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

2025-08-04 20:01; UTC

Uždarbis

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

2025-08-04 19:41; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Settle Lower -- Market Talk

2025-08-04 19:28; UTC

Rinkos pokalbiai

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

2025-08-04 19:07; UTC

Rinkos pokalbiai

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

2025-08-04 18:27; UTC

Rinkos pokalbiai

Gold Climbs on Rate Cut Speculation -- Market Talk

Akcijų palyginimas

Kainos pokytis

Ratos AB (Class B) Prognozė

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ratos AB (Class B)

Ratos AB (publ) is a private equity firm specializing in buyouts, turnarounds, add on acquisitions, and middle market transactions. The firm does not invest in early stages and in companies that operate in the arms industry, pornography, or are detrimental to the environment. It seeks to invest in unlisted medium sized companies. The firm invests in industry, construction and services, consumer, and technology sectors. The firm typically invests in the Nordic region, with focus on Sweden, Finland, Denmark, and Norway. It seeks to invest in companies with equity investments between SEK250 million ($23.57 million) and SEK5000 million ($471.57 million), sales value between SEK300 million ($28.29 million) and SEK5000 million ($471.57 million) and EBITDA greater than SEK50 million ($4.71 million). The firm takes both minority and majority stakes. The firm prefers to be the principal owner with a minimum holding of at least 20 percent and also seeks a board seat. It prefers to hold its investment between five to ten years. Ratos AB (publ) was founded in 1934 and is based in Stockholm, Sweden.